Patent · US Active

Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex

US8685384B2 · kind B2 · utility

7Cited by
55References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 24, 2007
Grant dateApr 1, 2014
Priority date
Expiry dateApr 27, 2030

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic peptides of cancer or infected cells. The claimed methods comprise the constructing of a nucleotide sequence encoding a secretable modified heat shock protein, expressing the sequence in an appropriate host cell, recovering the immunogenic complexes from the cell culture and the cells, and purifying the immunogenic complexes by affinity chromatography. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the genetic sequence. The complexes can be used as a vaccine to elicit specific immune responses against cancer or infected cells, and to treat or prevent cancer or infectious diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.